Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5356481 | 0.85 | TDP1 (0.45) | CA1CA2MEN1KMT2ATSHR | |
| SCHEMBL15705458 | 0.81 | CA1 (0.39) | CA1CA2MEN1KMT2AZDHHC7 | |
| SCHEMBL11648130 | 0.80 | ZDHHC7 (0.48) | CA1CA2MEN1KMT2AZDHHC7 | |
| SCHEMBL11650719 | 0.80 | CA1 (0.46) | CA1CA2MEN1KMT2AZDHHC7 | |
| Hydrochloric Acid SCHEMBL15665182 | 0.79 | CA1 (0.38) | CA1CA2MEN1KMT2AZDHHC7 | |
| SCHEMBL5854707 | 0.79 | ENPEP (0.32) | CA1CA2MEN1KMT2A | |
| SCHEMBL5694365 | 0.78 | ZDHHC7 (0.52) | CA1CA2MEN1KMT2AZDHHC7 | |
| SCHEMBL5855659 | 0.78 | TDP1 (0.43) | CA1CA2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15670490 | 0.77 | CA1 (0.35) | CA1CA2MEN1KMT2ATSHR | |
| SCHEMBL7242957 | 0.77 | FAAH (0.47) | CA1CA2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610733-B2 | Antiestrogen, therapeutic agent for breast cancer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-26 | — | — | US | disclosed |
| US-20030125571-A1 | Optically active chroman and thiochroman derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-03 | — | — | US | disclosed |
| EP-1241165-A1 | OPTICALLY ACTIVE CHROMAN AND THIOCHROMAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125571-A1 | Optically active chroman and thiochroman derivatives | NR5A1, CYP19A1, SHBG | CA1 697/4885CA2 429/4885MEN1 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.